Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

Resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) with activating EGFR mutations generally involve development of acquired secondary or tertiary EGFR mutations, such as T790M or C797S. However, case reports have demonstrated that actionable receptor tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Horn, Leora, Cruz, Marcelo, Vafai, Davood, Lovly, Christine M., Spradlin, Allison, Williamson, Michael J., Dagogo-Jack, Ibiayi, Johnson, Adrienne, Miller, Vincent A., Gadgeel, Shirish, Ali, Siraj M., Schrock, Alexa B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203818/
https://www.ncbi.nlm.nih.gov/pubmed/28838400
http://dx.doi.org/10.1016/j.lungcan.2017.07.006

Ejemplares similares

Ejemplares similares